Addex Therapeutics Regains Rights To GABAB PAM Portfolio, Citing Termination Of Indivior Research Collaboration
Share
Why It Matters
Addex got back rights to a medicine project from a partner. Now watch if the company can move this project forward faster.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.